Significant Effect of VEGFA Polymorphisms on the Clinical Outcome of Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Cetuximab

References

• Ferlay J , ShinH-R , BrayF , FormanD , MathersC , ParkinDM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 . Int. J. Cancer127 , 2893 – 2917 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Vincenzi B , SchiavonG , SillettaM , SantiniD , ToniniG . The biological properties of cetuximab . Crit. Rev. Oncol. Hematol.68 ( 2 ), 93 – 106 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , LenzHJ , KöhneCHet al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer . J. Clin. Oncol.33 , 692 – 700 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Custodio A , FeliuJ . Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations . Crit. Rev. Oncol. Hematol.85 , 45 – 81 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Perrotte P , MatsumotoT , InoueKet al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice . Clin. Cancer Res.5 , 257 – 265 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Bruns CJ , HarbisonMT , DavisDWet al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms . Clin. Cancer Res.6 , 1936 – 1948 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Luwor RB , LuY , LiX , MendelsohnJ , FanZ . The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression . Oncogene24 , 4433 – 4441 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Vincenzi B , SantiniD , RussoAet al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan . Pharmacogenomics8 , 319 – 327 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Grimminger PP , DanenbergP , DellasKet al. Biomarkers for cetuximab-based neoadjuvantradiochemotherapy in locally advanced rectal cancer . Clin. Cancer Res.17 , 3469 – 3477 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hansen TF , JakobsenA . Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer . Pharmacogenomics12 , 1681 – 1693 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Koukourakis MI , PapazoglouD , GiatromanolakiAet al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer . Lung Cancer46 , 293 – 298 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Yang B , CrossDF , OllerenshawMet al. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus . J. Diabetes Complications17 , 1 – 6 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Renner W , KotschanS , HoffmannCet al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels . J. Vasc. Res.37 , 443 – 448 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Azzopardi N , LecomteT , TernantDet al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients . Clin. Cancer Res.17 , 6329 – 6337 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Brogan IJ , KhanN , IsaacK , HutchinsonJA , PravicaV , HutchinsonIV . Novel polymorphisms in the promoter and 5’ UTR regions of the human vascular endothelial growth factor gene . Hum. Immunol.60 , 1245 – 1249 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Bruyère F , HovensCM , MarsonM-Net al. VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma . J. Urol.184 , 1273 – 1278 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tregouet D-A , BarbauxS , EscolanoSet al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction . Hum. Mol. Genet.11 , 2015 – 2023 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Tregouet DA , TiretL . Cox proportional hazards survival regression in haplotype-based association analysis using the stochastic-EM algorithm . Eur. J. Hum. Genet.12 , 971 – 974 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Ungerbäck J , ElanderN , DimbergJ , SöderkvistP . Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population . Mol. Med. Rep.2 , 435 – 439 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cacev T , LoncarB , SeiwerthS , SpaventiS , KapitanovicS . Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer . DNA Cell. Biol.27 , 569 – 574 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zhang W , GordonM , PressOAet al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab . Pharmacogenet. Genomics16 , 475 – 483 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Wang L , JiS , ChengZ . Association between polymorphisms in vascular endothelial growth factor gene and response to chemotherapies in colorectal cancer: a meta-analysis . PLoS ONE10 , e0126619 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shahbazi M , FryerAA , PravicaVet al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection . J. Am. Soc. Nephrol.13 , 260 – 264 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Stevens A , SodenJ , BrenchleyPE , RalphS , RayDW . Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter . Cancer Res.63 , 812 – 816 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Vallbohmer D . Molecular determinants of cetuximab efficacy . J. Clin. Oncol.23 , 3536 – 3544 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneC-H , HitreEet al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer . N. Engl. J. Med.360 , 1408 – 1417 ( 2009 ).
   PubMed Web of Science ®Google Scholar